As Southeast Asian businesses set their sights on overseas expansion, Hong Kong is becoming a pivotal gateway to access ...

HKEX CEO Bonnie Chan discusses the Hong Kong IPO outlook, highlighting a nearly 90% surge in IPO fundraising last year, signaling a strong return of confidence to Hong Kong.

Duality Biologics, a Chinese biotech specializing in antibody-drug conjugates (ADCs), has opted not to move forward at this time with a plan to list on the Hong Kong Stock Exchange. The company’s IPO ...

HKEX figures indicate that, in January, the exchange received 30 IPO applications in January, including seven A+H applications for firms already possessing mainland-listed (A) shares that wanted to ...

More than 100 new IPO applications are being processed by HKEX, he said. Increased investor interest has also spurred a revival in China's stock market this year, fueled by a surge in sentiment ...

About 100 companies were in the IPO pipeline, Bonnie Chan Yiting, CEO of HKEX, said last month. The city's high-quality and international professional-services sector could assist in further ...

According to financial data service Wind and HKEX, 40 companies have filed for IPOs on the main board of HKEX as of February 3, 2025, doubling from 20 seen in the same period last year.